Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Accumulated Expenses (2016 - 2025)

Protalix BioTherapeutics (PLX) has 10 years of Accumulated Expenses data on record, last reported at $745000.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $745000.0; the TTM value through Sep 2025 reached $745000.0, changed N/A, while the annual FY2024 figure was $1.3 million, 85.09% down from the prior year.
  • Accumulated Expenses reached $745000.0 in Q3 2025 per PLX's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.3 million in Q1 2025 and bottomed at $745000.0 in Q3 2025.
  • Average Accumulated Expenses over 3 years is $4.5 million, with a median of $2.2 million recorded in 2025.
  • The widest YoY moves for Accumulated Expenses: up 85.09% in 2024, down 85.09% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $9.0 million in 2023, then tumbled by 85.09% to $1.3 million in 2024, then crashed by 44.53% to $745000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $745000.0 in Q3 2025, $2.2 million in Q2 2025, and $9.3 million in Q1 2025.